Denali Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. 

CEO
Ryan J. Watts
CEORyan J. Watts
Employees
422
Employees422
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
422
Employees422

DNLI Key Statistics

Market cap
2.65B
Market cap2.65B
Price-Earnings ratio
-5.91
Price-Earnings ratio-5.91
Dividend yield
Dividend yield
Average volume
1.25M
Average volume1.25M
High today
$17.95
High today$17.95
Low today
$16.70
Low today$16.70
Open price
$17.48
Open price$17.48
Volume
1.86M
Volume1.86M
52 Week high
$24.35
52 Week high$24.35
52 Week low
$10.57
52 Week low$10.57

Stock Snapshot

With a market cap of 2.65B, Denali Therapeutics(DNLI) trades at $16.95. The stock has a price-to-earnings ratio of -5.91.

During the trading session on 2026-01-07, Denali Therapeutics(DNLI) shares reached a daily high of $17.95 and a low of $16.70. At a current price of $16.95, the stock is +1.5% higher than the low and still -5.6% under the high.

Trading volume for Denali Therapeutics(DNLI) stock has reached 1.86M, versus its average volume of 1.25M.

Over the past 52 weeks, Denali Therapeutics(DNLI) stock has traded between a high of $24.35 and a low of $10.57.

Over the past 52 weeks, Denali Therapeutics(DNLI) stock has traded between a high of $24.35 and a low of $10.57.

DNLI News

TipRanks 1d
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision

Claim 70% Off TipRanks Premium Denali Therapeutics ( (DNLI) ) has provided an update. On January 6, 2026, Denali Therapeutics outlined its key priorities and...

TipRanks 1d
Denali Therapeutics announces key milestones, priorities for 2026

Denali Therapeutics (DNLI) announced key anticipated milestones and priorities for 2026 across its portfolio of investigational therapies for neurodegenerative...

Analyst ratings

100%

of 17 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.